Comprehensive database of approved and investigational peptides. Research-backed information for educational purposes only.
Ozempic, Wegovy, Rybelsus
A long-acting GLP-1 receptor agonist that mimics the gut hormone glucagon-like peptide-1. Stimulates glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and acts on hypothalamic satiety centers to reduce appetite.
Mounjaro, Zepbound
A dual GIP and GLP-1 receptor agonist. Activates both incretin pathways simultaneously, producing more pronounced glycemic control and weight loss than GLP-1 monotherapy.
A triple agonist of GLP-1, GIP, and glucagon receptors. The glucagon component additionally boosts energy expenditure and hepatic fat oxidation in addition to appetite suppression from the incretin pathways.
Victoza, Saxenda
A once-daily GLP-1 receptor agonist. Mechanistically similar to semaglutide but with a shorter half-life requiring daily dosing.
Trulicity
Once-weekly GLP-1 receptor agonist fused to an IgG4-Fc fragment, extending half-life. Lowers HbA1c and offers cardiovascular benefit in established CV disease.
Byetta, Bydureon
A synthetic analog of exendin-4 (originally isolated from Gila monster saliva). Shorter-acting GLP-1 agonist — the first in the drug class.
A synthetic pentadecapeptide derived from a protective protein in gastric juice. Preclinical studies suggest it modulates nitric oxide pathways, promotes angiogenesis, and accelerates tissue repair.
A synthetic fragment of thymosin beta-4, an actin-sequestering peptide involved in cell migration, angiogenesis, and wound healing.
A synthetic analog of growth hormone–releasing hormone (GHRH) modified for extended half-life. Stimulates pituitary release of endogenous growth hormone.
A pentapeptide ghrelin receptor agonist (growth hormone secretagogue). Selectively stimulates GH release without significantly raising cortisol or prolactin.
A naturally occurring tripeptide that binds copper. In cosmetic and preclinical research it modulates collagen synthesis, wound healing, and oxidative stress pathways.
A synthetic non-selective melanocortin receptor agonist that stimulates melanogenesis and has off-target effects on sexual function via MC4R.
Geref
A synthetic 29-amino-acid fragment of GHRH that stimulates pituitary GH release. Was used as a diagnostic agent for GH deficiency.
A once-daily oral non-peptide small-molecule GLP-1 receptor agonist — designed to bypass the need for injections and without the absorption constraints of oral semaglutide.
A long-acting amylin analog that complements GLP-1 activity by targeting a distinct satiety pathway.
A dual glucagon/GLP-1 receptor agonist. Combines appetite suppression with glucagon-mediated increases in energy expenditure and hepatic lipid mobilization.
A dual GLP-1 / GLP-2 receptor agonist targeting metabolic and gut barrier function simultaneously.
Vyleesi
A cyclic heptapeptide melanocortin receptor agonist (primarily MC3/MC4) acting centrally on sexual arousal pathways.
A neuropeptide first isolated from cerebral venous blood of sleeping rabbits. Precise receptor and mechanism remain poorly characterized.
Zadaxin
A 28-amino-acid immunomodulatory peptide that enhances T-cell activity and interferon response pathways.
Egrifta
A synthetic GHRH analog that stimulates endogenous GH release. Approved specifically for HIV-associated lipodystrophy.